RIGL Relative Valuation
RIGL's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, RIGL is overvalued; if below, it's undervalued.
Historical Valuation
Rigel Pharmaceuticals Inc (RIGL) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -9.67. The fair price of Rigel Pharmaceuticals Inc (RIGL) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：47.80
Fair
12.16
PE
1Y
3Y
5Y
Trailing
Forward
6.10
EV/EBITDA
Rigel Pharmaceuticals Inc. (RIGL) has a current EV/EBITDA of 6.10. The 5-year average EV/EBITDA is -9.38. The thresholds are as follows: Strongly Undervalued below -56.20, Undervalued between -56.20 and -32.79, Fairly Valued between 14.03 and -32.79, Overvalued between 14.03 and 37.44, and Strongly Overvalued above 37.44. The current Forward EV/EBITDA of 6.10 falls within the Historic Trend Line -Fairly Valued range.
9.40
EV/EBIT
Rigel Pharmaceuticals Inc. (RIGL) has a current EV/EBIT of 9.40. The 5-year average EV/EBIT is 6.71. The thresholds are as follows: Strongly Undervalued below -323.72, Undervalued between -323.72 and -158.51, Fairly Valued between 171.92 and -158.51, Overvalued between 171.92 and 337.14, and Strongly Overvalued above 337.14. The current Forward EV/EBIT of 9.40 falls within the Historic Trend Line -Fairly Valued range.
3.25
PS
Rigel Pharmaceuticals Inc. (RIGL) has a current PS of 3.25. The 5-year average PS is 2.80. The thresholds are as follows: Strongly Undervalued below -0.73, Undervalued between -0.73 and 1.03, Fairly Valued between 4.56 and 1.03, Overvalued between 4.56 and 6.33, and Strongly Overvalued above 6.33. The current Forward PS of 3.25 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/OCF
Rigel Pharmaceuticals Inc. (RIGL) has a current P/OCF of 0.00. The 5-year average P/OCF is 5.75. The thresholds are as follows: Strongly Undervalued below -63.66, Undervalued between -63.66 and -28.96, Fairly Valued between 40.45 and -28.96, Overvalued between 40.45 and 75.15, and Strongly Overvalued above 75.15. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/FCF
Rigel Pharmaceuticals Inc. (RIGL) has a current P/FCF of 0.00. The 5-year average P/FCF is 1.92. The thresholds are as follows: Strongly Undervalued below -19.84, Undervalued between -19.84 and -8.96, Fairly Valued between 12.79 and -8.96, Overvalued between 12.79 and 23.67, and Strongly Overvalued above 23.67. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
Rigel Pharmaceuticals Inc (RIGL) has a current Price-to-Book (P/B) ratio of 7.28. Compared to its 3-year average P/B ratio of -0.82 , the current P/B ratio is approximately -989.70% higher. Relative to its 5-year average P/B ratio of 1.90, the current P/B ratio is about 282.95% higher. Rigel Pharmaceuticals Inc (RIGL) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -5.55%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -7.68% , the current FCF yield is about -100.00% lower.
7.31
P/B
Median3y
-0.82
Median5y
1.90
7.95
FCF Yield
Median3y
-5.55
Median5y
-7.68
Competitors Valuation Multiple
The average P/S ratio for RIGL's competitors is 0.00, providing a benchmark for relative valuation. Rigel Pharmaceuticals Inc Corp (RIGL) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 25.59%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of RIGL increased by 181.69% over the past 1 year. The primary factor behind the change was an increase in Margin Expansion from 22.46 to 40.17.
The secondary factor is the P/E Change, contributed 77.25%to the performance.
Overall, the performance of RIGL in the past 1 year is driven by Margin Expansion. Which is more sustainable.
People Also Watch
FAQ
Is Rigel Pharmaceuticals Inc (RIGL) currently overvalued or undervalued?
What is Rigel Pharmaceuticals Inc (RIGL) fair value?
How does RIGL's valuation metrics compare to the industry average?
What is the current P/B ratio for Rigel Pharmaceuticals Inc (RIGL) as of Dec 05 2025?
What is the current FCF Yield for Rigel Pharmaceuticals Inc (RIGL) as of Dec 05 2025?
What is the current Forward P/E ratio for Rigel Pharmaceuticals Inc (RIGL) as of Dec 05 2025?